Intravenous immunoglobulin for the treatment of childhood encephalitis
Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents su...
Main Authors: | Iro, M, Martin, N, Absoud, M, Pollard, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cochrane Collaboration
2017
|
Similar Items
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
by: Hill, M, et al.
Published: (2023) -
Childhood encephalitis in the United Kingdom - epidemiology, trends in hospital admissions and the role of intravenous immunoglobulin
by: Iro, M
Published: (2018) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
by: Iro, MA, et al.
Published: (2024) -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
by: Simon Nadel, et al.
Published: (2023-11-01) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
by: Mildred A Iro, et al.
Published: (2024-04-01)